Both TPA and SCC-Ag levels are prognostic even in high-risk stage lb-Ila cervical carcinoma as determined by a stratification analysis

Objective: To determine the prognostic values of tissue polypeptide antigen (TPA), squamous cell carcinoma antigen (SCC-Ag), and carcinoembryonic antigen (CEA) in the sera of cervical carcinoma patients, especially in those with a poor prognosis.

Methods: In this retrospective study, the preoperative serum SCC-Ag, TPA, and CEA were analyzed in 779 patients with cervical squamous cell carcinoma of stage Ib-IIa who received radical hysterectomy and pelvic lymph node dissection (RAH-PLND) between 1984 and 1994.

Results: Due to poor predictive value and poor correlation between serum CEA and clinico-pathological factors, CEA was abandoned in this study. Elevated TPA and SCC-Ag levels, pelvic lymph node metastasis (PLNM), lymphvascular space involvement (LVSI) and deep stromal invasion (DSI) were associated with poor survival time by univariate analysis. The correlation study showed that elevated serum TPA was significantly related to PLNM, LVSI, and DSI (p = 0.004, 0.008, and 0.021, respectively), and SCC-Ag was related to PLNM and bulky tumor size (p = 0.001 and 0.02, respectively). In the multivariate analysis, only PLNM and LVSI remained independently significant indicating poor survival. Further stratification studies by PLNM and LVSI showed that elevated TPA levels could even indicate higher recurrence rates in patients with PLNM (p = 0.045), as well as SCC-Ag in patients with LVSI (p = 0.038).

Conclusions: The results suggest that both elevated TPA and SCC-Ag levels depicting poor prognosis in stage Ib-IIa cervical SCC, especially indicates a group of high-risk patients who may need more aggressive therapy.

Squamous cell carcinoma antigen; Tissue polypeptide antigen; Stage IB-IIA cervical carcinoma

[1] Yuan C.C..WangP.H., Lai C.R., Yen M.S., Chen C.Y., Juang C. M.: "Prognosis-predicting system based on factors related to survival of cervical carcinoma'. Int. J. Gynecol. Obstet., 1998, 63, 163.

[2] Yuan C. C., Wang P. H., Lai C. R., Tsu E. J., Yen M. S., Ng H. T.: "Recurrence and survival analyses of 1,115 cervical cancer patients treatment with radical hysterectomy". Gynecol. Obstet Invest., 1999, 47, 127.

[3] Alvarez R. D., Soong S. J., Kinney W. K. et al.: "Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix". Gynecol. Oneal., 1989, 35, 130.

[4] Smiley L.M .,B urke T. W.,S ilva E. G.,M orrisM .,G ershenson D M., Wharton J. T.: "Prognostic factors on stage IB squamous cervieal cancer patients with low risk for recurrence". Obstet Gynecol.,1991, 77, 271.

[5] Sigurdsson K.,H arfnkelsson J., Geirsson G., Gudumundsson J., Salvarsdottir A.: "Screening as a prognostic factor in cervical cancer: Analysis of survival and prognostic factor based on Icelandic population data". Gynecol. Oneal., 1991, 43, 64.

[6] Scambia G., Benedetti Panici P., Foti E., et al.: "Squamous cell carcinoma antigen: prognostic significance and role in the monitaring of neoadjuvant chemotherapy response in cervical cancer" J. Clin. Oneal., 1994, 12, 2309.

[7] Kainz C., Zeisler H., Kohlberger P. et al.: "Prognostic value of cytokeratins and carcinoembryonic antigen expre、sion in primary surgically treated cervical cancer". Anticancer Res., 1994. 14, 667.

[8] Gaarenstroom K. N., Bonfrer J. M., Korse C. M., Kenter G. G., Kenemanns P.: "Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer". Anticancer Res., 1997, 17, 2955.

[9] Brioschi P.A., Bischof P., Delafosse C., Kraner F.: "Squamous cell carcinoma antigen (SCC-A) values related to clinical outcome of preinvasive and invasive cervical carcinoma". Int. J. Cancer. 1991, 47, 376.

[10] Duk J. M., Groenier K. H.,D eBruijn H. W. A.,H ollema H., Ten Hoar K. A., Van der Zee A. G. J., Aalders J. G.: "Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma". J. Clin. Oneal., 1996, 14, 111.

[11] Gaarenstroom K. N., Bonfrer J.M. G., Kenter G. G., Korse C. M., Hart A. A. M., Trimbos J. B.. Helmerhhorse T. H. J. M.: "Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer". Cancer, 1995, 76, 807.

[12] Juang C. M., Wang P.H., Yen M. S., Lai C. R., Ng H. T., Yuan C. C.: "Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FJGO stage 1B and IlA squamous cell carcinoma of the uterine cervix". Gynecol. Oncol., 2000, 76, 103.

[13] Chung C. K., Nahhas W. A., Stryker J. A., Curry S. L., Abt J. A., Mortel R.: "Analysis of factors contributing to treatment failure in stage lb and Ila carcinoma of the cervix". Am. J. Ohstet. Gynecol., 1980, 138, 550.

[14] Creasman W. T.: "FIGO news. Modifications in the staging for stage I vulvar and stage I cervical cancer". Int. J. Gynecol. Obstet., 1978, 52, 138.

[15] Hsieh C. Y.. Chang D. Y.,H uang S. C., Yen M. L., Juang G. T., Ouyang P. C.: "Serum squamous cell carcinoma antigen in gynecologic malignancies with special reference to cervical cancer" Taiwan. I. Hsueh. Hui. Tm. Chih., 1989, 88, 797.

[16] Bonfrer J.M., Gaarenstroom K. N., Korse C. M., Van Bunnmgen B. N., Kenemans P.: "Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen". Anticancer Res., 1997, 17, 2329.

[17] Lam C. P., Yuan C. C.. Jeng F. S. et al.: "Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers". Chin. Med. J. (Taipei), 1992, 50, 7.

[18] Cox D.R.: "Regression models and life tables." R. J. Stat. Soc. B. 1972, 34, 187.

[19] Biorklund B., Bjorklund V.: "Specificity and basis of the tissue polypeptide antigen." Cancer Detect. Prevent., 1983, 6, 41.

[20] Schick C., Kamachi Y., Bartuski A.J., et al.: "A squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsinlike proteinase cathepsin G and mast cell chimase". J. Bio. Chem. 1997, 272, 1849.

[21] Kamura T., Tsukamoto N., Tsuruchi N. et al.: "Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy". Cancer, 1992, 69, 181.

[22] Inoue T.,I noue I.,T sukamoto N. et al.: "Stage lb,I la,I Ib cervix cancer, post-surgical staging, and prognosis". Cancer, 1990, 65, 1923.

[23] Chung C. K., Nahhas W. A., Stryker J. A., Curry S. L., Abt J. A., Mortel R.: "Analysis of factors contributing to treatment failure in stage lb and Ila carcinoma of the cervix". Am. J. Obstet. Gynecol., 1980, 138, 550.

[24] Gaaarenstroom K. N., Kenter G. G., Bonfrer, J. M. G.. Korse C M., Van De Vijver M. J., Fleurcn G. J., Brimbos J. B.: "Can initial serum cyfra 21-1 SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastasis or prognosis?" Gynecol. Oncol., 2000, 77, 164.

[25] Avall-Lundqvist E. H.,S jovall K.,N ilsson B. R.,E neroth P. H. E.: "Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and cal25 in cervical carcinoma." Eur. J. Cancer, 1992, 28A, 1695.

[26] Hong J. H., Tsai C. S., Chang J. T., Wang C. C., Lai C.H., Lee S. P., et al.: "The prognostic 、ignificance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy". Int. J. Radial. Oncol. BioPhys., 1998, 41, 823.

[27] Bolger B. S., Dabbas M.,L opes A.,M onaghan J.M.: "Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma". Gynecol. Oncol., 1997, 65, 309.

[28] Sevin B. U.,L u Y.,B loch C. A.,N adijM .,K oechli 0. R.,A verette H. E.: "Surgically defined prognostic parameters in patients with early cervical carcinoma". Cancer, 1996, 78, 1438.